+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast to 2030- Product Image
Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896719
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The oncology drugs market is experiencing significant momentum, shaped by rapid advancements in scientific research and shifting demands from healthcare stakeholders worldwide. Companies positioned along the entire value chain are engaging with technological innovation, increased collaboration, and ongoing global changes to meet evolving patient and regulatory expectations.

Market Snapshot: Oncology Drugs Market Growth

The Oncology Drugs Market grew from USD 210.00 billion in 2024 to USD 225.54 billion in 2025. It is expected to continue growing at a CAGR of 7.72%, reaching USD 328.16 billion by 2030. This robust growth trajectory reflects a strong convergence of clinical demand and R&D investments. Decision-makers are adapting to intensifying competition, complex reimbursement frameworks, and rapidly shifting treatment paradigms as they identify new opportunities for leadership in oncology therapeutic development.

Scope & Segmentation

This report provides comprehensive analysis across all levels of the oncology drugs market with a dual focus on therapeutic innovation and value chain optimization. Segmentation includes:

  • Drug Classes: Chemotherapy agents, hormonal therapy agents, immunotherapy agents (such as CAR T-cell therapy, checkpoint inhibitors including CTLA-4 and PD-1/PD-L1 inhibitors), and targeted therapy agents (monoclonal antibodies, chimeric/humanized antibodies, small molecule inhibitors including CDK and tyrosine kinase inhibitors).
  • Routes of Administration: Injectables (intramuscular, intravenous, subcutaneous) and oral regimens supporting convenience and adherence.
  • Molecule Type: Biologics (including monoclonal antibodies, vaccines) and small molecules offering a range of innovation and bioavailability.
  • Clinical Indications: Blood cancers (leukemia, acute myeloid, chronic lymphocytic, lymphoma), breast, lung, colorectal, and prostate cancers.
  • End Users: Hospitals, research institutes, and specialty clinics for cancer drug deployment.
  • Distribution Channels: Hospital, online, and retail pharmacies, advancing patient access and integrated supply chains.
  • Regions Covered: Americas (multiple key US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including UK, Germany, France, Russia, multiple regional leaders), and Asia-Pacific (China, India, Japan, Australia, and other growing markets).
  • Key Companies Profiled: Analysis covers both established pharmaceutical firms and emerging biotech innovators such as AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Merck, Pfizer, Roche, Sun Pharma, Takeda, and others.

Key Takeaways for Oncology Drugs Decision-Makers

  • The market’s progression is heavily driven by continual innovation in genomic profiling, precision medicine, and immuno-oncology modalities. Development pipelines now increasingly emphasize both targeted therapies and immunomodulatory agents designed to personalize cancer care and improve outcomes.
  • Digitization and the adoption of real-world evidence are changing the nature of clinical development, patient engagement, and regulatory strategies. Industry partnerships, cross-disciplinary consortia, and the use of big data are expediting the translation of research to clinical application.
  • Regulatory and reimbursement complexities remain significant, prompting manufacturers and payers to adopt agile frameworks and collaborative operating models. Strategic investments in advanced manufacturing and digital health assets are proving critical for operational resilience.
  • Regional approaches in supply chain and policy adaptation are yielding new market entry strategies, particularly in emerging Asia-Pacific markets and regions with developing healthcare infrastructure. Localized partnerships and capacity building are strengthening market position and access.
  • Sustainable competitive advantage is increasingly defined by the ability to integrate technology with cross-sectoral collaboration, driving both product differentiation and improved patient access in increasingly competitive and policy-sensitive environments.

Tariff Impact: Navigating New US Trade Policies

The introduction of US tariffs on imported active pharmaceutical ingredients and finished oncology drugs in 2025 has significantly influenced global sourcing and cost structures. Manufacturers are adjusting their supply chains and exploring near-shoring or vertical integration options, with pronounced effects on biologics and advanced manufacturing inputs. These pressures have triggered fresh investments in regional production and enhanced supply resilience. Downstream partners, including contract research organizations and clinical trial sponsors, are balancing increased operating costs by adapting timelines and budget allocations, while local partnerships and diversified supplier networks are becoming key risk mitigation tools.

Methodology & Data Sources

Analysis is rooted in a multi-tiered approach, blending thorough secondary research from peer-reviewed journals, regulatory publications, and corporate filings with structured primary interviews of oncology thought leaders, payers, and commercial executives. Quantitative data were validated through proprietary and public databases, and findings were further refined by scenario planning and sensitivity analyses. This ensures actionable, reliable market intelligence.

Why This Report Matters

  • Delivers unbiased, segment-level insights enabling leadership teams to define effective strategies for investment, R&D, and risk management within the oncology drugs market.
  • Enables benchmarking of technological, clinical, and supply chain trends crucial to navigating policy, pricing, and access challenges across multiple geographies.

Conclusion

Grounded in rigorous analysis, this report empowers senior leaders to anticipate market shifts and guide organizations toward sustainable growth in oncology therapeutics. Stakeholders can leverage segmentation insights, industry benchmarks, and actionable recommendations to support strategic decision-making in this dynamic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing governmental support through favorable reimbursement policies for cancer drugs
5.1.1.2. Rising investments in cancer research and development activities from both public and private sectors
5.1.1.3. Increasing prevalence of various types of cancers worldwide demands a surge in oncology drug development
5.1.2. Restraints
5.1.2.1. Side effects associated with cancer treatments
5.1.3. Opportunities
5.1.3.1. Increased collaboration with biotech firms to fast-track development of innovative oncology drugs
5.1.3.2. Integrating telemedicine with oncology practices to reach underserved and remote patient populations
5.1.4. Challenges
5.1.4.1. Complexity associated with conducting oncology drug trials
5.2. Market Segmentation Analysis
5.2.1. Route of Administration: Rising preference for injectable routes due to its rapid delivery of chemotherapeutic agents
5.2.2. End User: Rising use of oncology drugs in hospitals due to high volume of cancer patients
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Oncology Drugs Market, by Drug Class
6.1. Introduction
6.2. Chemotherapy Agents
6.2.1. Alkylating Agents
6.2.2. Antimetabolites
6.3. Hormonal Therapy Agents
6.4. Immunotherapy Agents
6.4.1. CAR T-Cell Therapy
6.4.2. Checkpoint Inhibitors
6.4.2.1. CTLA-4 Inhibitors
6.4.2.2. PD-1/PD-L1 Inhibitors
6.5. Targeted Therapy Agents
6.5.1. Monoclonal Antibodies
6.5.1.1. Chimeric
6.5.1.2. Humanized
6.5.2. Small Molecule Inhibitors
6.5.2.1. Cyclin-Dependent Kinase Inhibitors
6.5.2.2. Tyrosine Kinase Inhibitors
7. Oncology Drugs Market, by Route of Administration
7.1. Introduction
7.2. Injectable
7.2.1. Intramuscular
7.2.2. Intravenous
7.2.3. Subcutaneous
7.3. Oral
8. Oncology Drugs Market, by Molecule Type
8.1. Introduction
8.2. Biologics
8.2.1. Monoclonal Antibodies
8.2.2. Vaccines
8.3. Small Molecules
9. Oncology Drugs Market, by Indication
9.1. Introduction
9.2. Blood Cancer
9.2.1. Leukemia
9.2.1.1. Acute Myeloid Leukemia
9.2.1.2. Chronic Lymphocytic Leukemia
9.2.2. Lymphoma
9.2.2.1. Hodgkin Lymphoma
9.2.2.2. Non-Hodgkin Lymphoma
9.3. Breast Cancer
9.4. Colorectal Cancer
9.5. Lung Cancer
9.6. Prostate Cancer
10. Oncology Drugs Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
11. Oncology Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Americas Oncology Drugs Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Oncology Drugs Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Oncology Drugs Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Scenario Analysis
15.3.1. AstraZeneca gets the nod to launch cancer drug
15.3.2. Lupin's strategic US launch of cost-effective generic doxorubicin targets key oncology markets
15.3.3. FDA approves novel IL-15 receptor agonist for enhancing response in BCG-unresponsive NMIBC treatment
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ONCOLOGY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. ONCOLOGY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. ONCOLOGY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. ONCOLOGY DRUGS MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 23. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 28. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 29. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ONCOLOGY DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 120. CANADA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 121. CANADA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 122. CANADA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 123. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. CANADA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 127. CANADA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 128. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 129. CANADA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. CANADA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 131. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 132. CANADA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 133. CANADA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. CANADA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 144. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 145. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 148. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 149. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 150. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. MEXICO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 179. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 180. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 181. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 197. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 198. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 199. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 201. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 202. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 206. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 207. CHINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 208. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. CHINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 210. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 211. CHINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 214. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 215. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 216. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 217. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 218. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 219. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 220. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. INDIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 224. INDIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 225. INDIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. INDIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 227. INDIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 228. INDIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. INDIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 231. INDIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 232. INDIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 233. INDIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. INDIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 235. INDIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 236. INDIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 237. INDIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. INDIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 242. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. INDONESIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 258. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 259. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 261. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 262. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 265. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 266. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 267. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 269. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 270. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 271. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. JAPAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 275. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 276. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 277. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 278. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 280. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 282. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 283. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 284. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 286. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 287. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 288. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. MALAYSIA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 320. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 321. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 322. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. SINGAPORE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 325. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 326. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 327. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 328. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 329. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 330. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 331. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 332. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 333. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 334. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 335. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 336. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 337. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 338. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 339. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. SOUTH KOREA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 341. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 342. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 343. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 344. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 345. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 346. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 347. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 348. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 349. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 350. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 351. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 352. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 353. TAIWAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD MILLION)
TABLE 354. TAIWAN ONCOLOGY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Oncology Drugs market report include:
  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Après-demain SA
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Bristol-Myers Squibb Company
  • C.H. Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Roche Holding AG
  • Shorla Oncology
  • Sun Pharmaceutical Industries Ltd
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 225.54 Billion
Forecasted Market Value ( USD ) by 2030 $ 328.16 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route of Administration, Therapy Line, Mechanism of Action, Formulation - Global Forecast to 2030 - Product Image

Generic Oncology Drugs Market by Drug Type, Indication, Distribution Channel, Route of Administration, Therapy Line, Mechanism of Action, Formulation - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Cancer Drugs Market by Distribution Channel, End User, Molecule Type, Administration Route, Therapy Type, Drug Class - Global Forecast to 2030 - Product Image

Cancer Drugs Market by Distribution Channel, End User, Molecule Type, Administration Route, Therapy Type, Drug Class - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Cancer Immunotherapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Cancer Immunotherapy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Immunotherapy Drugs - Global Strategic Business Report - Product Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From

About the Market

The Chemotherapy Agent market within the Healthcare Services sector is a rapidly growing industry. It is composed of a variety of products and services that are used to treat cancer and other diseases. These products and services include drugs, medical devices, and other treatments. The market is driven by the increasing prevalence of cancer and other diseases, as well as the development of new treatments and technologies. The Chemotherapy Agent market is highly competitive, with many companies offering a wide range of products and services. Companies in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Roche. These companies are constantly innovating and developing new products and services to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.